Alcobra (ADHD) Submits Protocol To FDA For Phase 2b Clinical Study Of Metadoxine Extended Release (MDX) In The Treatment Of Fragile X Syndrome
4/10/2014 3:05:18 PM
TEL AVIV, Israel, April 10, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that it has submitted a protocol to the FDA for a Phase IIb clinical trial for its MDX product candidate for the treatment of patients with Fragile X Syndrome.
Help employers find you! Check out all the jobs and post your resume.
comments powered by